Summit Therapeutics Inc. (SMMT)
SMMT Stock Price Chart
Explore Summit Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze SMMT price movements and trends.
SMMT Company Profile
Discover essential business fundamentals and corporate details for Summit Therapeutics Inc. (SMMT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Mar 2015
Employees
159.00
Website
https://www.summittxinc.comCEO
Robert W. Duggan
Description
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Financial Timeline
Browse a chronological timeline of Summit Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.26, while revenue estimate is $108.84k.
Earnings released on 30 Apr 2026
EPS came in at -$0.24 surpassing the estimated -$0.33 by +27.27%.
Earnings released on 23 Feb 2026
EPS came in at -$0.29 falling short of the estimated -$0.10 by -182.54%.
Earnings released on 20 Oct 2025
EPS came in at -$0.31 falling short of the estimated -$0.18 by -76.37%.
Earnings released on 11 Aug 2025
EPS came in at -$0.76 falling short of the estimated -$0.09 by -736.91%.
Earnings released on 1 May 2025
EPS came in at -$0.09 surpassing the estimated -$0.09 by +3.25%.
Earnings released on 24 Feb 2025
EPS came in at -$0.08 surpassing the estimated -$0.08 by +2.21%.
Earnings released on 30 Oct 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%.
Earnings released on 6 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 1 May 2024
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 20 Feb 2024
EPS came in at -$0.04 .
Earnings released on 7 Nov 2023
EPS came in at -$0.03 .
Earnings released on 9 Aug 2023
EPS came in at -$0.02 , while revenue for the quarter reached $235.00k .
Earnings released on 11 May 2023
EPS came in at -$0.06 .
Earnings released on 9 Mar 2023
EPS came in at -$0.07 surpassing the estimated -$0.26 by +73.08%, while revenue for the quarter reached $705.00 .
Earnings released on 9 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.26 by +46.15%, while revenue for the quarter reached $220.00k .
Earnings released on 11 Aug 2022
EPS came in at -$0.17 surpassing the estimated -$0.27 by +37.04%, while revenue for the quarter reached $235.00k .
Earnings released on 11 May 2022
EPS came in at -$0.22 surpassing the estimated -$0.28 by +21.43%, while revenue for the quarter reached $250.00k .
Earnings released on 17 Mar 2022
EPS came in at -$0.28 falling short of the estimated -$0.27 by -3.70%, while revenue for the quarter reached $251.00k .
Earnings released on 15 Nov 2021
EPS came in at -$0.20 surpassing the estimated -$0.29 by +31.03%, while revenue for the quarter reached $1.31m , beating expectations by +76.63k%.
Earnings released on 11 Aug 2021
EPS came in at -$0.27 falling short of the estimated -$0.18 by -50.00%, while revenue for the quarter reached $57.00k , meeting expectations.
SMMT Stock Performance
Access detailed SMMT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
